Lluis Puig (Luis Puig, L Puig, L Puig Sanz, Luís Puig, Lluís Puig)

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2014-2023
Publications (10 Years): 101

Top Venues

Journal of the European Academy of Dermatology and Venereology : JEADV

The British journal of dermatology

The Journal of dermatological treatment

International journal of molecular sciences

Universitat Autònoma de Barcelona (PHD)

This page only lists publications with an associated author ORCID identifier.

Education History

Universitat Autònoma de Barcelona

Spain

PHD

Publications

Paolo Gisondi, David Simon, Ivette Alarcon, Effie Pournara, Lluis Puig
Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review. The Journal of dermatological treatment 34 (1) (2023)
Lluís Rusiñol, Lluis Puig
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. International journal of molecular sciences 24 (4) (2023)
Gemma Camiña-Conforto, Laura Mateu-Arrom, Anna López-Ferrer, Lluis Puig
Bimekizumab in the Treatment of Plaque Psoriasis: Focus on Patient Selection and Perspectives. Patient preference and adherence 17 (2023)
Laura Mateu-Arrom, Lluis Puig
Genetic and Epigenetic Mechanisms of Psoriasis. Genes 14 (8) (2023)
Paolo Gisondi, David Simon, Ivette Alarcon, Effie Pournara, Lluis Puig
Immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients receiving secukinumab: a literature review. The Journal of dermatological treatment (2023)
Helena Iznardo, Esther Roé, Esther Serra Baldrich, Lluis Puig
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics 15 (2) (2023)
Lluís Rusiñol, Lluis Puig
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. International journal of molecular sciences 24 (4) (2023)
Guillermo Sánchez-Rodríguez, Lluis Puig
Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies. International journal of molecular sciences 24 (12) (2023)
Antonio Costanzo, Mar Llamas Velasco, Gabriella Fabbrocini, Aldo Cuccia, Raquel Rivera-Díaz, Kristian Gaarn Du Jardin, Ismail Kasujee, Lluis Puig, Y José Manuel Carrascosa
Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate-to-severe plaque psoriasis patients in conditions close to clinical practice. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Elena Carmona-Rocha, Lluis Puig
Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium. Immunotherapy (2023)
Marie Aleth Richard, Carle Paul, Tamar Nijsten, Paolo Gisondi, Carmen Salavastru, Charles Taïeb, Alex Stratigos, Myrto Trakatelli, Lluis Puig, null null
The journey of patients with skin diseases from the first consultation to the diagnosis in a representative sample of the European general population from the EADV burden of skin diseases study. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Paolo Gisondi, Lluis Puig, Marie Aleth Richard, Carle Paul, Tamar Nijsten, Charles Taïeb, Alex Stratigos, Myrto Trakatelli, Carmen Salavastru, null null
Quality of life and stigmatization in people with skin diseases in Europe: A large survey from the 'burden of skin diseases' EADV project. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Alvaro Gonzalez-Cantero, W H Boehncke, J De Sutter, J L Zamorano, J Lambert, Lluis Puig
Statins and psoriasis: Position statement by the Psoriasis Task Force of the European Society of Dermatology and Venerology. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Lluis Puig
Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination. The British journal of dermatology 188 (2) (2023)
Lluis Puig, E Daudén, M Cuervas-Mons, C Novella, C Guisado
Persistence and effectiveness of guselkumab treatment in patients with moderate-to-severe plaque psoriasis in a non-interventional real-world setting: the SPRING study. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Marie Aleth Richard, Pierre Wolkenstein, Carle Paul, Tamar Nijsten, Paolo Gisondi, Carmen Salavastru, Charles Taïeb, Myrto Trakatelli, Lluis Puig, Alex Stratigos, null null
Ethnicity and skin conditions in Europe: a large survey from the "Burden of Skin Diseases" EADV project. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Lluis Puig, Siew Eng Choon, A B Gottlieb, S Marrakchi, J C Prinz, R Romiti, Y Tada, D von Bredow, M Gooderham
Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals, and disease management. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Helena Iznardo, Esther Roé, Esther Serra Baldrich, Lluis Puig
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics 15 (2) (2023)
Giampiero Girolomoni, Laura Savage, Paolo Gisondi, Åke Svensson, Emmanuel Mahé, Matthias Augustin, Lluis Puig
Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review. Dermatology and therapy (2023)
Marie Aleth Richard, Carle Paul, Tamar Nijsten, Paolo Gisondi, Carmen Salavastru, Charles Taïeb, Myrto Trakatelli, Lluis Puig, Alex Stratigos, null null
Public perception of dermatologists in Europe: Results from a population-based survey. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Alexander Egeberg, Lars Erik Kristensen, Lluis Puig, Phoebe Rich, Saxon D Smith, Alyssa Garrelts, Kyoungah See, Thorsten Holzkaemper, Konstantinos Fotiou, Christopher Schuster
Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24-28 and 48-52 weeks. The Journal of dermatological treatment 34 (1) (2023)
Lluis Puig, Siew Eng Choon, Alice B Gottlieb, Slaheddine Marrakchi, Jörg C Prinz, Ricardo Romiti, Yayoi Tada, Dorothea von Bredow, Melinda J Gooderham
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. Journal of the European Academy of Dermatology and Venereology : JEADV 37 (4) (2023)
Lluis Puig, Siew Eng Choon, Alice B Gottlieb, Slaheddine Marrakchi, Jörg C Prinz, Ricardo Romiti, Yayoi Tada, Dorothea von Bredow, Melinda J Gooderham
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. Journal of the European Academy of Dermatology and Venereology : JEADV 37 (4) (2023)
Guillermo Sánchez-Rodríguez, Lluis Puig
Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies. International journal of molecular sciences 24 (12) (2023)
Lluis Puig, Antonio Costanzo, Elke M G J de Jong, Tiago Torres, Richard B Warren, Robert Wapenaar, Sven Wegner, Patricia Gorecki, Talia Gramiccia, Maria Jazra, Jozefien Buyze, Curdin Conrad
Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for ≥ 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial. American journal of clinical dermatology (2023)
Lluís Rusiñol, Lluis Puig
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases. International journal of molecular sciences 24 (4) (2023)
Lluis Puig, Siew Eng Choon, Alice B Gottlieb, Slaheddine Marrakchi, Jörg C Prinz, Ricardo Romiti, Yayoi Tada, Dorothea von Bredow, Melinda J Gooderham
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Lluis Puig, Siew Eng Choon, Alice B Gottlieb, Slaheddine Marrakchi, Jörg C Prinz, Ricardo Romiti, Yayoi Tada, Dorothea von Bredow, Melinda J Gooderham
Generalized pustular psoriasis: A global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. Journal of the European Academy of Dermatology and Venereology : JEADV (2023)
Lluis Puig
Psoriasis treatment does not impair the immunogenicity of ChAOx1-S[recombinant] COVID-19 vaccination. The British journal of dermatology 188 (2) (2023)
Helena Iznardo, Esther Roé, Esther Serra Baldrich, Lluis Puig
Efficacy and Safety of JAK1 Inhibitor Abrocitinib in Atopic Dermatitis. Pharmaceutics 15 (2) (2023)
Guillermo Sánchez-Rodríguez, Lluis Puig
Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies. International journal of molecular sciences 24 (12) (2023)
Ana Maria Lé, Lluis Puig, Tiago Torres
Deucravacitinib for the Treatment of Psoriatic Disease. American journal of clinical dermatology 23 (6) (2022)
Lluis Puig
Psoriasis treatment: no more room on the summit? The British journal of dermatology 187 (6) (2022)
Katie Bechman, Emma S Cook, Nick Dand, Zenas Zee Ngai Yiu, Teresa Tsakok, Freya Meynell, Bolaji Coker, Alexandra Vincent, Herve Bachelez, Ines Barbosa, Matthew A Brown, Francesca Capon, Claudia R Contreras, Claudia De La Cruz, Paola Di Meglio, Paolo Gisondi, Denis Jullien, Jade Kelly, Jo Lydie Wilfried Lambert, Camille Lancelot, Sinéad M Langan, Kayleigh J Mason, Helen McAteer, Lucy Moorhead, Luigi Naldi, Katherine Jones, Lluis Puig, Phyllis I Spuls, Tiago Torres, Dominic Urmston, Amber Vesty, Richard Bruce Warren, Hoseah Waweru, John Weinman, Christopher Ernest Maitland Griffiths, Jonathan N W N Barker, Catherine H Smith, James B Galloway, Satveer K Mahil, null null
Vaccine hesitancy and access to psoriasis care during the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. The British journal of dermatology 187 (2) (2022)
Helena Iznardo, Lluis Puig
IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications. International journal of molecular sciences 23 (16) (2022)
Andreas Pinter, Lluis Puig, Knut Schäkel, Adam Reich, Shirin Zaheri, Antonio Costanzo, Tsen Fang Tsai, Saxon D Smith, Charles Lynde, Alan Brnabic, Catherine Reed, Julie Hill, Christopher Schuster, Elisabeth Riedl, Carle Paul
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). Journal of the European Academy of Dermatology and Venereology : JEADV 36 (11) (2022)
Helena Iznardo, E Vilarrasa, E Roé, Lluis Puig
Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (8) (2022)
Lluis Puig, Antonio Costanzo, Ernesto J Muñoz-Elías, Maria Jazra, Sven Wegner, Carle F Paul, Curdin Conrad
The biological basis of disease recurrence in psoriasis: a historical perspective and current models. The British journal of dermatology 186 (5) (2022)
Néboa Zozaya, Fernando Abdalla, Santiago Alfonso Zamora, Jesús Balea Filgueiras, Y José Manuel Carrascosa, Olga Delgado Sánchez, Francisco Dolz Sinisterra, Antonio J GarcíA Ruiz, Pedro Herranz Pinto, Antonio Manfredi, José Martínez Olmos, Paloma Morales de Los Ríos Luna, Lluis Puig, Sandra Ros, Álvaro HIdalgo-Vega
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis. Expert review of pharmacoeconomics & outcomes research 22 (6) (2022)
James G Krueger, Lluis Puig, Diamant Thaçi
Treatment Options and Goals for Patients with Generalized Pustular Psoriasis. American journal of clinical dermatology 23 (Suppl 1) (2022)
Kristian Reich, L Iversen, Lluis Puig, J Lambert, Ulrich Mrowietz, K Kaplan Saday, R B Warren
Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (8) (2022)
Silvia Vidal, Lluis Puig, José-Manuel Carrascosa-Carrillo, Álvaro González-Cantero, José-Carlos Ruiz-Carrascosa, Antonio-Manuel Velasco-Pastor
Correction: Vidal et al. From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. Int. J. Mol. Sci. 2021, 22 , 6740. International journal of molecular sciences 23 (5) (2022)
Marie Aleth Richard, C Paul, T Nijsten, Paolo Gisondi, C Salavastru, Charles Taïeb, M Trakatelli, Lluis Puig, A Stratigos, null null
Prevalence of most common skin diseases in Europe: a population-based study. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (7) (2022)
Lluís Rusiñol, Gemma Camiña-Conforto, Lluis Puig
Biologic treatment of psoriasis in oncologic patients. Expert opinion on biological therapy (2022)
Kim A Papp, M G Lebwohl, Lluis Puig, M Ohtsuki, S Beissert, J Zeng, S Rubant, R Sinvhal, Y Zhao, A M Soliman, G Alperovich, C Leonardi
Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. The British journal of dermatology (2021)
Victoria Amat-Samaranch, Eugènia Agut-Busquet, Eva Vilarrasa, Lluis Puig
New perspectives on the treatment of hidradenitis suppurativa. Therapeutic advances in chronic disease 12 (2021)
Kristian Reich, Curdin Conrad, Lars Erik Kristensen, Saxon D Smith, Lluis Puig, Phoebe Rich, Christophe Sapin, Thorsten Holzkaemper, Uffe Koppelhus, Christopher Schuster
Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. The Journal of dermatological treatment (2021)
Helena Iznardo, E Vilarrasa, Anna López-Ferrer, Lluis Puig
Real-world drug survival of guselkumab, ixekizumab and secukinumab for psoriasis. The British journal of dermatology 185 (3) (2021)
Mark Lebwohl, Ahmed M Soliman, Hongbo Yang, Jessie Wang, Jonathan Freimark, Lluis Puig
Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-Severe psoriasis. The Journal of dermatological treatment (2021)
S K Mahil, M Yates, S M Langan, Z Z N Yiu, T Tsakok, N Dand, Kayleigh J Mason, H McAteer, F Meynell, B Coker, A Vincent, D Urmston, A Vesty, J Kelly, C Lancelot, L Moorhead, Herve Bachelez, I N Bruce, Francesca Capon, C R Contreras, A P Cope, C De La Cruz, Paola Di Meglio, Paolo Gisondi, K Hyrich, D Jullien, J Lambert, H Marzo-Ortega, I McInnes, L Naldi, S Norton, Lluis Puig, R Sengupta, P Spuls, Tiago Torres, R B Warren, H Waweru, J Weinman, C E M Griffiths, J N Barker, M A Brown, J B Galloway, C H Smith, null null
Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. The British journal of dermatology 185 (1) (2021)
Andrew Blauvelt, M Ramharter, A D Cohen, W Xu, H Patel, C Schuster, E Riedl, Lluis Puig
An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis treated with ixekizumab from 16 clinical studies. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (11) (2021)
Helena Iznardo, Lluis Puig
Exploring the Role of IL-36 Cytokines as a New Target in Psoriatic Disease. International journal of molecular sciences 22 (9) (2021)
Carla Tubau, Lluis Puig
IL-13 antagonists in the treatment of atopic dermatitis. Immunotherapy 13 (4) (2021)
Kristian Reich, J B Hansen, Lluis Puig, Maria-Polina Konstantinou, R B Warren
Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (10) (2021)
Jennifer Beecker, Kim A Papp, J Dutz, Ronald B Vender, Robert Gniadecki, Curtis L Cooper, Paolo Gisondi, Melinda J Gooderham, C H Hong, M G Kirchhof, C W Lynde, C Maari, Y Poulin, Lluis Puig
Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (4) (2021)
Silvia Vidal, Lluis Puig, José-Manuel Carrascosa-Carrillo, Álvaro González-Cantero, José-Carlos Ruiz-Carrascosa, Antonio-Manuel Velasco-Pastor
From Messengers to Receptors in Psoriasis: The Role of IL-17RA in Disease and Treatment. International journal of molecular sciences 22 (13) (2021)
Jo Lambert, Jes Birger Hansen, Anne Sohrt, Lluis Puig
Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab. Dermatology and therapy 11 (4) (2021)
Helena Iznardo, Lluis Puig
The interleukin-1 family cytokines in psoriasis: pathogenetic role and therapeutic perspectives. Expert review of clinical immunology 17 (2) (2021)
Helena Iznardo, Lluis Puig
Dual inhibition of IL-17A and IL-17F in psoriatic disease. Therapeutic advances in chronic disease 12 (2021)
Cristina Garcia-Melendo, Xavier Cubiró, C López-Sánchez, M Turienzo, A Mozos, Lluis Puig
Saprochaete capitata disseminated infection presenting as macular rash after haematopoietic stem cell transplantation. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (11) (2020)
Lluis Puig, T-F Tsai, T Bhutani, J Uy, P Ramachandran, M Song, Y You, M Gooderham, M Lebwohl
Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (8) (2020)
G Carretero, Y José Manuel Carrascosa, Lluis Puig, J L Sánchez-Carazo, A López-Ferrer, P Cueva, C Soria, Raquel Rivera-Díaz, Isabel Belinchón-Romero, null null
Definition of minimal disease activity in psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (2) (2020)
Miguel Nogueira, Lluis Puig, Tiago Torres
JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors. Drugs 80 (4) (2020)
Victoria Amat-Samaranch, Lluis Puig
Safety of calcipotriene and betamethasone dipropionate foam for the treatment of psoriasis. Expert opinion on drug safety 19 (4) (2020)
Jaime Piquero-Casals, Laura Martinez-Martinez, Agustín Alomar, Eduardo Rozas-Muñoz, Candido Juarez, Lluis Puig
LRP1/CD91 is highly expressed in monocytes from patients with vitiligo - even after repigmentation. Experimental dermatology 30 (3) (2020)
Lluis Puig
The safety of ixekizumab in psoriasis drug therapy. Expert opinion on drug safety 19 (2) (2020)
Lluis Puig
Head-to-head comparison of biologics in psoriasis: better acceleration does not necessarily win all races. The British journal of dermatology 184 (6) (2020)
Cristina López-Sánchez, Lluis Puig
Guselkumab in the treatment of moderate-to-severe plaque psoriasis. Immunotherapy 12 (6) (2020)
Tiago Torres, Lluis Puig
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. American journal of clinical dermatology 21 (3) (2020)
R B Warren, J B Hansen, Kristian Reich, C Paul, Lluis Puig
Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3. Journal of the European Academy of Dermatology and Venereology : JEADV 35 (2) (2020)
Xavier Cubiró, Eduardo Rozas-Muñoz, Pau Castel, Esther Roé Crespo, Cristina Garcia-Melendo, Lluis Puig, Eulalia Baselga
Clinical and genetic evaluation of six children with diffuse capillary malformation and undergrowth. Pediatric dermatology 37 (5) (2020)
Victoria Lucia Dávila Osorio, Helena Iznardo, Esther Roé, Lluis Puig, Eulalia Baselga
Propranolol-resistant infantile hemangioma successfully treated with sirolimus. Pediatric dermatology 37 (4) (2020)
Carla Tubau, Lluis Puig
Therapeutic targeting of the IL-13 pathway in skin inflammation. Expert review of clinical immunology 17 (1) (2020)
Bruce Strober, A Menter, C Leonardi, K Gordon, J Lambert, Lluis Puig, H Photowala, M Longcore, T Zhan, P Foley
Efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis by baseline demographics, disease characteristics and prior biologic therapy: an integrated analysis of the phase III UltIMMa-1 and UltIMMa-2 studies. Journal of the European Academy of Dermatology and Venereology : JEADV 34 (12) (2020)
Helena Iznardo, Lluis Puig
The safety of brodalumab for the treatment of psoriasis. Expert opinion on drug safety 19 (4) (2020)
Lluis Puig, Anna López-Ferrer
Biosimilars for the treatment of psoriasis. Expert opinion on biological therapy 19 (10) (2019)
Lluis Puig
Psoriasis Area and Severity Index vs. pharmacokinetics: can monitoring 4-week postinjection ustekinumab concentrations in patients with suboptimal response be clinically relevant? The British journal of dermatology 182 (2) (2019)
Lluis Puig, Jashin J Wu, Melinda J Gooderham, Yin You, Yaung-Kaung Shen, Bruce Randazzo, Francisco Kerdel
Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. The Journal of dermatological treatment 32 (5) (2019)
Lluis Puig
Guselkumab for the treatment of adults with moderate to severe plaque psoriasis. Expert review of clinical immunology 15 (6) (2019)
Elena Del Alcázar, Marta Ferran, Anna López-Ferrer, Jaime Notario, David Vidal, José Riera, Gloria Aparicio, Fernando Gallardo, Eva Vilarrasa, Mercè Alsina, Lluis Puig, Carlos Ferrándiz, Y José Manuel Carrascosa
Effectiveness and safety of ustekinumab 90 mg in patients weighing 100 kg or less: a retrospective, observational, multicenter study. The Journal of dermatological treatment 31 (3) (2019)
Michael J Cork, Laurent Eckert, Eric L Simpson, April Armstrong, Sébastien Barbarot, Lluis Puig, Giampiero Girolomoni, Marjolein de Bruin-Weller, Andreas Wollenberg, Yoko Kataoka, Anita Remitz, Stefan Beissert, Vera Mastey, Marius Ardeleanu, Zhen Chen, Abhijit Gadkari, Jingdong Chao
Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. The Journal of dermatological treatment 31 (6) (2019)
Lluis Puig
Significant weight loss improves and prevents psoriasis and psoriatic arthritis in obese patients: a Critically Appraised Topic and a call to action. The British journal of dermatology 181 (5) (2019)
Lluis Puig, Y José Manuel Carrascosa, Esteban Daudén, Sara Sulleiro, Cristina Guisado
Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study. The Journal of dermatological treatment 31 (4) (2019)
Donald E Stull, C E M Griffiths, I Gilloteau, Y Zhao, A Guana, A Y Finlay, B Sherif, K Houghton, Lluis Puig
Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis. The British journal of dermatology 178 (6) (2018)
Bruce Strober, A B Gottlieb, P C M van de Kerkhof, Lluis Puig, H Bachelez, E Chouela, S Imafuku, D Thaçi, H Tan, H Valdez, P Gupta, M Kaur, V Frajzyngier, R Wolk
Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. The British journal of dermatology 180 (1) (2018)
Francesca Sampogna, Lluis Puig, P Spuls, G Girolomoni, M A Radtke, B Kirby, M Brunori, P Bergmans, P Smirnov, J Rundle, A Castiglia, F Lavie, Carle F Paul
Reversibility of alexithymia with effective treatment of moderate-to-severe psoriasis: longitudinal data from EPIDEPSO. The British journal of dermatology 180 (2) (2018)
Jaime Notario, Gustavo Deza, Eva Vilarrasa, Francesc Valentí, Carlos Muñoz, Jordi Mollet, Vicenç Rocamora, Y José Manuel Carrascosa, Elena Del Alcázar, Mercè Alsina, David Vidal, Lluis Puig, Anna López-Ferrer, José Riera, Fernando Gallardo, Marta Ferran
Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain. The Journal of dermatological treatment 30 (5) (2018)
Arnon D Cohen, J J Wu, Lluis Puig, S Chimenti, Ronald B Vender, M Rajagopalan, R Romiti, C de la Cruz, L Skov, C Zachariae, Helen S Young, P Foley, J M van der Walt, L Naldi, E P Prens, Andrew Blauvelt
Biosimilars for psoriasis: worldwide overview of regulatory guidelines, uptake and implications for dermatology clinical practice. The British journal of dermatology 177 (6) (2017)
Andrew Blauvelt, C E M Griffiths, M Lebwohl, U Mrowietz, Lluis Puig, S Ball, L Zhang, E Edson-Heredia, M Warner, B Zhu, C-Y Lin, E Nikaï, D Dey, L Mallbris, Kristian Reich
Reaching complete or near-complete resolution of psoriasis: benefit and risk considerations. The British journal of dermatology 177 (2) (2017)
Boni E Elewski, Lluis Puig, Margaret Mordin, Isabelle Gilloteau, Bintu Sherif, Todd Fox, Ari Gnanasakthy, Charis Papavassilis, Bruce E Strober
Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab. The Journal of dermatological treatment 28 (6) (2017)
A López-Ferrer, A Laiz, Lluis Puig
The safety of ustekinumab for the treatment of psoriatic arthritis. Expert opinion on drug safety 16 (6) (2017)
Lluis Puig, Jaume Notario, Alberto Jiménez-Morales, David Moreno-Ramírez, Anna López-Ferrer, Irmina Gozalbo, Míriam Prades, Luis Lizán, Carles Blanch
Secukinumab is the most efficient treatment for achieving clear skin in psoriatic patients: a cost-consequence study from the Spanish National Health Service. The Journal of dermatological treatment 28 (7) (2017)
Lluis Puig
Cardiometabolic Comorbidities in Psoriasis and Psoriatic Arthritis. International journal of molecular sciences 19 (1) (2017)
Lluis Puig, Polina Putrik
Psoriasis: inequality or individualized care? The British journal of dermatology 176 (5) (2017)
Kristian Reich, I Zschocke, H Bachelez, E M G J de Jong, Paolo Gisondi, Lluis Puig, R B Warren, C Ortland, U Mrowietz, null null
A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). The British journal of dermatology 177 (1) (2017)
Lluis Puig
Choice of first-line biologic therapy in psoriasis: understanding the past and shaping the future? The British journal of dermatology 177 (3) (2017)
X Saenz-Sardà, C Carrato, L Pérez-Roca, Lluis Puig, C Ferrándiz, A Ariza, Maria-Teresa Fernandez-Figueras
Epithelial-to-mesenchymal transition contributes to invasion in squamous cell carcinomas originated from actinic keratosis through the differentiated pathway, whereas proliferation plays a more significant role in the classical pathway. Journal of the European Academy of Dermatology and Venereology : JEADV 32 (4) (2017)
S Planas-Ciudad, E Roé Crespo, I Sánchez-Carpintero, I J Frieden, A Martín-Santiago, P Redondo Bellón, E Moreno Artero, E Osier, Lluis Puig, E Baselga Torres
Infantile hemangiomas with minimal or arrested growth associated with soft tissue hypertrophy: a case series of 10 patients. Journal of the European Academy of Dermatology and Venereology : JEADV 31 (11) (2017)
A A Navarini, A D Burden, F Capon, U Mrowietz, Lluis Puig, S Köks, K Kingo, C Smith, J N Barker, null null
European consensus statement on phenotypes of pustular psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV 31 (11) (2017)
G Carretero, Lluis Puig, Y José Manuel Carrascosa, L Ferrándiz, R Ruiz-Villaverde, P de la Cueva, I Belinchon, E Vilarrasa, R Del Rio, J L Sánchez-Carazo, A López-Ferrer, F Peral, S Armesto, N Eiris, J Mitxelena, J Vilar-Alejo, M A Martin, C Soria, null null
Redefining the therapeutic objective in psoriatic patients candidates for biological therapy. The Journal of dermatological treatment 29 (4) (2017)

Lluis Puig.css-eqlu8i{font-size:small;padding-left:4px;} (Luis Puig, L Puig, L Puig Sanz, Luís Puig, Lluís Puig)

Publication Activity (10 Years)

Top Topics

Top Venues

Lluis Puig (Luis Puig, L Puig, L Puig Sanz, Luís Puig, Lluís Puig)